Quantcast
Last updated on April 16, 2014 at 13:39 EDT

Latest Protein kinases Stories

2009-03-12 13:58:42

A U.S. study has determined an enzyme known for its connections with cancer, diabetes, heart disease and stroke also helps create and maintain the brain. Washington University School of Medicine researchers in St. Louis discovered that when they selectively disabled the enzyme AMPK in mouse embryos, the animal's overall brain size was reduced by 50 percent, the cerebrum and cerebellum were shrunken and the mice died within three weeks of birth. The study showed the version of AMPK they...

2009-02-10 10:17:55

A new drug that blocks cancer's main source of growth has been created in the lab and proven effective in mice, scientists are reporting. It is now being readied for clinical trials in patients. Far more potent than similar compounds already in clinical trial, the drug short-circuits the normal ability of cells to sense the need to grow and divide -- a signal that cancer cells exploit to spread in the body. The scientists are working with clinicians to test the drug's effectiveness against a...

2009-01-30 09:13:55

Scientists have uncovered an interesting connection between two important protein kinase signaling pathways that are associated with cancer. The research, published by Cell Press in the January 30th issue of the journal Molecular Cell, may direct new therapeutic strategies for multiple types of cancer.The protein kinase LKB1 is a known tumor suppressor and the LKB1-AMPK signaling pathway couples energy metabolism with cell growth, proliferation and survival. "Mutations in LKB1 are not...

2009-01-16 13:45:22

Scientists from the Scripps Research Institute and the Genomics Institute of the Novartis Research Foundation have found a specific mutation that leads to the development of severe autoimmune kidney disease in mice. The research sheds light on the basic biology of the immune system, as well as on the effectiveness of drugs such as the anti-leukemia medication Gleevec/Imatinib.The study was published in the January 16, 2009 edition (Volume 33, No. 1) of the journal Molecular Cell.In the study,...

2009-01-16 12:39:31

Molecular details of bacterial drug resistance indicate possible role for kinase inhibitorsBacteria hunker down and survive antibiotic attack when a protein flips a chemical switch that throws them into a dormant state until treatment abates, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan.16 edition of Science."For antibiotics to work, bacteria have to be growing. Dormancy stops everything, allowing some bacteria to persist after treatment," said senior...

2008-12-04 11:51:00

NEW ROCHELLE, N.Y., Dec. 4 /PRNewswire/ -- Researchers are taking a closer look at the phosphoinositide 3-kinase (PI3-kinase) pathway as studies continue to demonstrate that inhibiting this biological route suppresses tumor growth, reports Genetic Engineering & Biotechnology News (GEN). The pathway is involved in angiogenesis, cell growth, differentiation, and survival. In addition, it is part of the PI3/AKT/mTOR pathway, which plays a key role in cancer, according to the December issue...

2008-10-23 09:00:38

Exelixis, a development-stage biotechnology company, has reported positive interim data from a Phase I dose-escalation trial of XL765, a small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The trial is being carried out in patients with metastatic or unresectable solid tumors for which known effective measures do not exist or are no longer effective. In the trial, XL765 is orally...

2008-10-22 06:00:08

Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL765, a novel small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The trial is being carried out in patients with metastatic or unresectable solid tumors for which known effective measures do not exist or are no longer effective. Dr. Ben Markman, Medical Oncologist, Vall D'Hebron University...

2008-10-22 06:00:08

Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL147, a novel small molecule inhibitor of phosphoinositide-3 kinase (PI3K), which is implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The trial is enrolling patients with metastatic or unresectable solid tumors for which known effective measures do not exist or are no longer effective. The trial is being conducted at Vall D'Hebron University...

2008-08-28 12:01:22

US-based drug discovery company Semafore Pharmaceuticals has announced the discovery of novel multi-targeted kinase inhibitors that demonstrated significant anticancer activity in preclinical studies. Of 50 compounds identified, SF2523 and SF2506 have been chosen for additional evaluation based on their ability to inhibit multiple kinases, including PI3K, mTOR, DNA-PK and PIM-1. Evaluation of SF2523 in a 232 kinase panel screen showed that the compound selectively and potently inhibits...